Clinical trial
Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer
NCT00003257 · Aventis Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00003257 |
|---|---|
| Title | Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer |
| Official title | A Phase II, Multicenter, Open Label Study to Evaluate Effectiveness and Safety of AdCMV-p53 Administered by Intra-Tumoral Injections in 39 Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Lead sponsor | Aventis Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Biological |
| Interventions | Ad5CMV-p53 gene |
| Enrollment | 39 |
| Start date | Jan 1, 1998 |
| First posted | Sep 10, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: